Biopharma Business

Tag "clinical development programs"

Verona Pharma pens trial deal with QuintilesIMS for RPL554

Last year, Cardiff, U.K.-based Verona secured £44.7 million ($65.6 million) from big-name investors on both sides of the Atlantic for work on its PDE3/PDE4 inhibitor RPL554, and has now teamed

Read Full Article

Upcoming Events


The Magazine

New Subscriber

Subscribe Here